New hope for pancreatic cancer: drug combo aims to shrink tumors

NCT ID NCT07578337

First seen May 13, 2026 · Last updated May 13, 2026

Summary

This study tests whether adding a hedgehog inhibitor (NLM-001) and two immunotherapy drugs (botensilimab and balstilimab) to standard chemotherapy can shrink tumors better than chemotherapy alone in people with advanced pancreatic cancer that hasn't been treated yet. About 40 adults with stage IV pancreatic cancer will take part. The goal is to see if the new combination improves response rates while keeping side effects manageable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Complexo Hospitalario Universitario de Santiago

    Santiago de Compostela, La Coruña, Spain

    Contact

    Contact

  • Hospital Clínic Barcelona

    Barcelona, Barcelona, Spain

    Contact

    Contact

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, Spain

    Contact

    Contact

  • Hospital Universitario Miguel Servet

    Zaragoza, Aragon, Spain

    Contact

    Contact

  • Hospital Universitario Virgen de la Victoria

    Málaga, Málaga, Spain

    Contact

    Contact

  • Hospital Universitario de Donostia

    San Sebastián, Gipuzkoa, Spain

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.